Drugs / Anti-Human Thymocyte Immunoglobulin, Rabbit
Anti-Human Thymocyte Immunoglobulin, Rabbit
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT05996393 | Sep 2023 → Feb 2025 | aplastic anemia | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04509791 Comparator | Nov 2020 → Dec 2024 | type 1 diabetes mellitus | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-Human Thymocyte Immunoglobulin, Rabbit | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04509791 ↗ |
| Known as | anti-thymocyte immunoglobulin | “anti-thymocyte immunoglobulin (ATG)” NCT05996393 ↗ |
| Known as | ATG | “anti-thymocyte immunoglobulin (ATG)” NCT05996393 ↗ |
| Route | Intravenous | “ATG was administered by an intravenous infusion over 2 consecutive days.” PMID 40976248 ↗ Sep 2025 |